Drug Type Hematopoietic stem cell therapy |
Synonyms Umbilical cord blood megakaryocytes(HemaCell), XJ-002, XJ-MK-002 + [1] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Thrombocytopenia | Phase 1 | China | 28 Aug 2025 | |
| Anemia, Aplastic | IND Approval | China | 03 Mar 2026 | |
| Bernard-Soulier Syndrome | Preclinical | United States | 04 Apr 2025 | |
| Congenital Amegakaryocytic Thrombocytopenia | Preclinical | China | 19 Oct 2024 |
NCT07110090 (NEWS) Manual | Phase 1 | - | aghxqadvip(vvhpobgofy) = 未发生 dnjcmvaniv (fvsjackjgz ) View more | Positive | 26 Sep 2025 |





